Results

1–10 of 116 results for clinical trials

Ixoberogene Soroparvovec (Ixo-vec) IVT Gene Therapy for Neovascular AMD: First Time 26-Week Interim Analysis Results from the Phase 2 LUNA Study
Charles C Wykoff, MD, PhD, FASRS
Updates from the Field
2024
Masked Safety Data from ZETA-1, an Ongoing 24-Week Phase 2 Clinical Trial of APX3330, an Oral Therapeutic Being Developed for the Treatment of Diabetic Retinopathy
Michael J Allingham, MD, PhD
Annual Meeting Talks
2022
Interim Subretinal Gene Therapy Safety Results in Two Phase 1/2 Open-label, Dose-Escalation Clinical Trials to Treat Achromatopsia
Lejla Vajzovic, MD, FASRS
Annual Meeting Talks
2022
Outcomes of the HORNBILL Study: A Phase I/IIa Trial Investigating BI 764524 in Patients With Diabetic Macular Ischemia
Quan Dong Nguyen, MD, MSc, FARVO, FASRS
Updates from the Field
2024
Detailed Baseline Demographics and Disease Characteristics of Patients With Geographic Atrophy Enrolled in the Phase 3 OAKS and DERBY Clinical Trials
On Demand Cases, Courses, and Papers
2022
GATHER2 Phase 3 Efficacy Results and GATHER2 Phase 3 Safety Results
Jeffrey S. Heier, MD
Arshad M. Khanani, MD, MA, FASRS
Updates from the Field
2022
Geographic Access Disparities of Clinical Trials in Neovascular Age-Related Macular Degeneration in the United States
Rebecca Soares, MD
Annual Meeting Talks
2021
Baseline DR Severity and Time to DME Resolution in Patients Treated With Ranibizumab in the RIDE and RISE Clinical Trials
Katherine E Talcott, MD
Annual Meeting Talks
2021
Impact of Race on Vision Outcomes in Ranibizumab-Treated Patients With Diabetic Macular Edema: A Meta-Analysis of 5 Clinical Trials
M. Ali Khan, MD, FACS, FASRS
Annual Meeting Talks
2021
Preliminary Results from a First-in-human Phase I/II Gene Therapy Study (FOCUS) of Subretinally Delivered GT005, an Investigational AAV2 Vector, in Patients with Geographic Atrophy Secondary to Age-related Macular Degeneration
Jared S. Nielsen, MD, MBA
Updates from the Field
2022